

# Importance of Complete Skin Clearance on Quality of Life: Analysis of Three Phase 3 Studies of Brodalumab

April Armstrong,<sup>1</sup> Andrew Blauvelt,<sup>2</sup> Scott Drew,<sup>3</sup> Roger Ho,<sup>4</sup> Abby Jacobson<sup>5</sup>

<sup>1</sup>University of Southern California, Los Angeles, CA; <sup>2</sup>Oregon Medical Research Center, Portland, OR; <sup>3</sup>OhioHealth, Marion, OH; <sup>4</sup>The Ronald O. Perleman Department of Dermatology, New York University School of Medicine, New York, NY; <sup>5</sup>Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ

## INTRODUCTION

- Complete skin clearance is an important treatment goal for patients with psoriasis<sup>1</sup>
- Evidence shows that complete skin clearance is associated with several benefits over almost-clear skin, including improved quality of life<sup>1</sup>
- Brodalumab is a human anti-interleukin-17 receptor A monoclonal antibody that is efficacious in treating moderate-to-severe psoriasis<sup>2-4</sup>
- In the phase 3 brodalumab trials AMAGINE-1, -2, and -3, 42%, 44%, and 37% of patients receiving brodalumab 210 mg every 2 weeks (Q2W), respectively, achieved a psoriasis area and severity index score of 100 (PASI 100) at week 12<sup>2,3</sup>

## OBJECTIVE

- To explore whether patients with psoriasis achieving complete skin clearance experienced greater improvements in quality of life than those achieving a good but less-than-complete response

## METHODS

- Data for this post hoc analysis were pooled from the nonplacebo groups of the 12-week induction phases of three phase 3 clinical trials (AMAGINE-1/-2/-3) of brodalumab in patients with moderate-to-severe plaque psoriasis
- Patients included in the analysis were treated with brodalumab (140 or 210 mg) or ustekinumab (45 or 90 mg) and had achieved complete skin clearance, defined as 100% improvement in PASI score (PASI 100), or good but incomplete skin clearance, defined as PASI 90 to <100
- Patient-reported outcomes were used to evaluate quality of life (Figure 1), stratified by complete or good but incomplete skin clearance

**Figure 1.** Quality of life measures assessed in this post hoc analysis.




HADS, hospital anxiety and depression scale; MCS, mental component summary; PCS, physical component summary; SF-36, Short Form 36 health survey; WLQ, work limitations questionnaire.

## RESULTS

- At week 12, mean (standard deviation [SD]) hospital anxiety and depression scale anxiety and depression scores were numerically lower for patients achieving PASI 100 (anxiety, 4.75 [3.30]; depression, 2.90 [3.00]) than for patients achieving PASI 90 to <100 (anxiety, 5.09 [4.16]; depression, 3.55 [3.18]; Figure 2)
- Numerically fewer work limitations, indicated by mean (SD) work limitations questionnaire scores, were reported by patients achieving PASI 100 (2.29 [3.11]) than by those achieving PASI 90 to <100 (3.00 [3.58]; Figure 2)


**Figure 2.** Mean quality of life measure scores by categories of complete skin clearance (PASI 100) or good but incomplete response (PASI 90 to <100) at week 12.



The HADS is a 14-item questionnaire, with higher scores indicating worse anxiety or depression.<sup>4</sup> The WLQ measures on-the-job limitations due to health problems and health-related productivity loss, with higher scores indicating greater impairment.<sup>5</sup> HADS, hospital anxiety and depression scale; PASI, psoriasis area and severity index; WLQ, work limitations questionnaire.

- At week 12, mean (SD) SF-36 mental component summary (MCS) and physical component summary (PCS) scores were similar among patients who achieved PASI 90 to <100 (MCS, 51.39 [7.68]; PCS, 52.53 [7.82]) and PASI 100 (MCS, 52.96 [7.99]; PCS, 52.38 [8.71]; Figure 3)

**Figure 3.** Mean MCS and PCS scores by categories of complete skin clearance (PASI 100) or good but incomplete response (PASI 90 to <100) at week 12.



SF-36 scores include 8 health domains yielding the MCS and PCS scores, with higher scores indicating better health.<sup>6</sup> MCS, mental component summary; PASI, psoriasis area and severity index; PCS, physical component summary; SF-36, Short Form 36 health survey.

## CONCLUSIONS

- Achievement of complete skin clearance (PASI 100) was associated with greater numeric improvements in quality-of-life measures than achievement of a good but less-than-complete response in patients with moderate-to-severe plaque psoriasis
- These results suggest that therapies likely to help patients achieve complete skin clearance, such as brodalumab, are important to consider when making treatment decisions

**Acknowledgments:** This study was sponsored by Ortho Dermatologics. Medical writing support was provided by MedThink SciCom and funded by Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US, LLC.

**References:** 1. Takeshita et al. *J Am Acad Dermatol*. 2014;71:633-641. 2. Siliq [package insert]. Valeant Pharmaceuticals North America LLC; 2017. 3. Lebwohl et al. *N Engl J Med*. 2015;373:1318-1328. 4. Papp et al. *Br J Dermatol*. 2016;175:273-286. 5. Allaire. *Arthritis Rheum*. 2003;49(suppl 5S):S85-S89. 6. Grassi et al. *Value Health*. 2010;13:469-478.